A 6-year-old boy with a confirmed diagnosis of multi-system Langerhans cell histiocytosis involving skin and bone fails to respond to initial therapy with vinblastine and corticosteroids. The care team is considering second-line therapies and sends tumor tissue for molecular analysis. The results reveal a BRAF V600E pathogenic variant. Which of the following therapeutic agents directly targets the identified aberrant signaling pathway in this patient’s disease?